KR20230047203A - 암 치료 - Google Patents

암 치료 Download PDF

Info

Publication number
KR20230047203A
KR20230047203A KR1020237010047A KR20237010047A KR20230047203A KR 20230047203 A KR20230047203 A KR 20230047203A KR 1020237010047 A KR1020237010047 A KR 1020237010047A KR 20237010047 A KR20237010047 A KR 20237010047A KR 20230047203 A KR20230047203 A KR 20230047203A
Authority
KR
South Korea
Prior art keywords
cancer
aurka
tsa
pharmaceutical composition
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020237010047A
Other languages
English (en)
Korean (ko)
Inventor
미하엘 에이치. 폴리메로포울로스
루이스 윌리엄 리카멜레
크리스티안 라베단
Original Assignee
반다 파마슈티칼즈, 인코퍼레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 반다 파마슈티칼즈, 인코퍼레이티드. filed Critical 반다 파마슈티칼즈, 인코퍼레이티드.
Publication of KR20230047203A publication Critical patent/KR20230047203A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020237010047A 2013-08-22 2014-08-22 암 치료 Abandoned KR20230047203A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361869039P 2013-08-22 2013-08-22
US61/869,039 2013-08-22
KR1020217033186A KR20210127821A (ko) 2013-08-22 2014-08-22 암 치료
PCT/US2014/052209 WO2015027121A2 (en) 2013-08-22 2014-08-22 Cancer treatment

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217033186A Division KR20210127821A (ko) 2013-08-22 2014-08-22 암 치료

Publications (1)

Publication Number Publication Date
KR20230047203A true KR20230047203A (ko) 2023-04-06

Family

ID=51794948

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020237010047A Abandoned KR20230047203A (ko) 2013-08-22 2014-08-22 암 치료
KR1020217033186A Ceased KR20210127821A (ko) 2013-08-22 2014-08-22 암 치료
KR1020217002758A Active KR102315528B1 (ko) 2013-08-22 2014-08-22 암 치료
KR1020167004630A Ceased KR20160033779A (ko) 2013-08-22 2014-08-22 암 치료
KR1020177032020A Ceased KR20170126018A (ko) 2013-08-22 2014-08-22 암 치료

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020217033186A Ceased KR20210127821A (ko) 2013-08-22 2014-08-22 암 치료
KR1020217002758A Active KR102315528B1 (ko) 2013-08-22 2014-08-22 암 치료
KR1020167004630A Ceased KR20160033779A (ko) 2013-08-22 2014-08-22 암 치료
KR1020177032020A Ceased KR20170126018A (ko) 2013-08-22 2014-08-22 암 치료

Country Status (12)

Country Link
US (5) US20160199323A1 (https=)
EP (2) EP3616754A1 (https=)
JP (4) JP2016528297A (https=)
KR (5) KR20230047203A (https=)
CN (2) CN110585184A (https=)
AU (4) AU2014308700A1 (https=)
CA (1) CA2921036A1 (https=)
CL (1) CL2016000397A1 (https=)
EA (1) EA037667B1 (https=)
ES (1) ES2755983T3 (https=)
MX (1) MX381429B (https=)
WO (1) WO2015027121A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230047203A (ko) * 2013-08-22 2023-04-06 반다 파마슈티칼즈, 인코퍼레이티드. 암 치료
BR112016003609B1 (pt) * 2013-08-22 2021-04-27 Vanda Pharmaceuticals Inc Uso de tricostatina a em tratamento de mieloma múltiplo (mm)
WO2021016203A1 (en) * 2019-07-19 2021-01-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Pdlim2 as a biomarker for cancer and as an anti-cancer treatment target
WO2023168201A1 (en) * 2022-03-01 2023-09-07 Vanda Pharmaceuticals Inc. Trichostatin a (tsa) sensitivity in the treatment of tumors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218478A (en) * 1979-01-05 1980-08-19 Ruiko Oiwa Trichostatin as an antiprotozoal agent
CA1265431A (en) 1985-01-08 1990-02-06 Roderick John Macdonald Electrode device for flare stack ignitor
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
WO2002060430A1 (en) * 2001-02-01 2002-08-08 Cornell Research Foundation, Inc. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
DK2238982T3 (da) * 2003-06-27 2013-01-28 Astellas Pharma Inc Terapeutisk middel til blødt væv-sarcom
DK2537942T3 (en) 2004-05-21 2015-12-14 Trustees Of The University Of Arkansas System Board Of Use of genudtryksprofilering to predict survival in cancer patients
GB0519405D0 (en) 2005-09-23 2005-11-02 Univ Aberdeen Cancer therapy prognosis and target
WO2007067516A2 (en) * 2005-12-06 2007-06-14 Duke University Multiple myeloma
EP2023912A2 (en) 2006-05-26 2009-02-18 Celgene Corporation Methods and compositions using immunomodulatory compounds in combination therapy
CA2574531C (en) * 2007-01-19 2016-10-25 The University Of British Columbia Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
US20110301055A1 (en) 2008-12-05 2011-12-08 Nicholas James Dickens Methods for determining a prognosis in multiple myeloma
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
WO2013071247A1 (en) * 2011-11-10 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Gene expression signatures of neoplasm responsiveness to theraphy
EP2602330A1 (en) 2011-12-07 2013-06-12 Palacky University, Olomouc Method of determination of cancer cell drug sensitivity towards Aurora kinase inhibitors and overcoming their resistance
JO3754B1 (ar) * 2012-06-04 2021-01-31 Pharmacyclics Llc أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
KR20230047203A (ko) * 2013-08-22 2023-04-06 반다 파마슈티칼즈, 인코퍼레이티드. 암 치료
BR112016003609B1 (pt) 2013-08-22 2021-04-27 Vanda Pharmaceuticals Inc Uso de tricostatina a em tratamento de mieloma múltiplo (mm)
DE102014117278A1 (de) 2014-11-25 2016-05-25 Krones Ag Hubeinheit zum Anheben und Absenken eines Behälters in einer Behälterbehandlungsanlage

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1, BLOOD, 15 MARCH 2007, VOLUME 109, NUMBER 6
Bortezomib Reduces the Tumorigenicity of Multiple Myeloma via Downregulation of Upregulated Targets in Clonogenic Side Population Cells, PLOS ONE, March 2013, Volume 8, Issue 3, e56954

Also Published As

Publication number Publication date
NZ716668A (en) 2021-02-26
MX2016002307A (es) 2016-06-15
WO2015027121A2 (en) 2015-02-26
CN105579101A (zh) 2016-05-11
US20210324093A1 (en) 2021-10-21
ES2755983T3 (es) 2020-04-24
AU2019261718A1 (en) 2019-11-28
KR20170126018A (ko) 2017-11-15
JP2016528297A (ja) 2016-09-15
KR20210013343A (ko) 2021-02-03
JP2021105005A (ja) 2021-07-26
EA201690445A1 (ru) 2016-06-30
CN110585184A (zh) 2019-12-20
US20180256522A1 (en) 2018-09-13
KR20210127821A (ko) 2021-10-22
EP3036007B1 (en) 2019-10-09
AU2021261882A1 (en) 2021-12-02
JP2019167351A (ja) 2019-10-03
US12590162B2 (en) 2026-03-31
CA2921036A1 (en) 2015-02-26
AU2014308700A1 (en) 2016-02-25
JP2023088996A (ja) 2023-06-27
US11078289B2 (en) 2021-08-03
EP3036007A2 (en) 2016-06-29
US11667718B2 (en) 2023-06-06
US20190211107A1 (en) 2019-07-11
AU2022202183B2 (en) 2023-09-28
KR102315528B1 (ko) 2021-10-21
EP3616754A1 (en) 2020-03-04
KR20160033779A (ko) 2016-03-28
US20230257471A1 (en) 2023-08-17
MX381429B (es) 2025-03-12
US20160199323A1 (en) 2016-07-14
US10265282B2 (en) 2019-04-23
AU2021261882B2 (en) 2022-04-14
WO2015027121A3 (en) 2015-05-14
AU2022202183A1 (en) 2022-04-21
CL2016000397A1 (es) 2017-03-17
EA037667B1 (ru) 2021-04-28

Similar Documents

Publication Publication Date Title
US12590162B2 (en) Cancer treatment
US20240342120A1 (en) Multiple myeloma treatment
US8748428B2 (en) Use of a PKC inhibitor
NZ716668B2 (en) Cancer treatment
HK1226349A1 (en) Cancer treatment
HK1226349B (en) Cancer treatment

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A17-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PC1902 Submission of document of abandonment before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1902